These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25192260)

  • 1. Exploring the scaffold universe of kinase inhibitors.
    Hu Y; Bajorath J
    J Med Chem; 2015 Jan; 58(1):315-32. PubMed ID: 25192260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping Biological Activities to Different Types of Molecular Scaffolds: Exemplary Application to Protein Kinase Inhibitors.
    Dimova D; Bajorath J
    Methods Mol Biol; 2018; 1825():327-337. PubMed ID: 30334211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural diversity and potency range distribution of scaffolds from compounds active against current pharmaceutical targets.
    Kayastha S; Dimova D; Stumpfe D; Bajorath J
    Future Med Chem; 2015; 7(2):111-22. PubMed ID: 25686001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target family-directed exploration of scaffolds with different SAR profiles.
    Hu Y; Bajorath J
    J Chem Inf Model; 2011 Dec; 51(12):3138-48. PubMed ID: 22091691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and Activity Profile Relationships Between Drug Scaffolds.
    Hu Y; Bajorath J
    AAPS J; 2015 May; 17(3):609-19. PubMed ID: 25697829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analogues.
    Furtmann N; Hu Y; Bajorath J
    J Med Chem; 2015 Jan; 58(1):252-64. PubMed ID: 25054653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 9. Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective.
    Hu Y; Kunimoto R; Bajorath J
    Chem Biol Drug Des; 2017 Jun; 89(6):834-845. PubMed ID: 27933727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic assessment of scaffold hopping versus activity cliff formation across bioactive compound classes following a molecular hierarchy.
    Stumpfe D; Dimova D; Bajorath J
    Bioorg Med Chem; 2015 Jul; 23(13):3183-91. PubMed ID: 25982076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward an efficient approach to identify molecular scaffolds possessing selective or promiscuous compounds.
    Yongye AB; Medina-Franco JL
    Chem Biol Drug Des; 2013 Oct; 82(4):367-75. PubMed ID: 23659738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focused library with a core structure extracted from natural products and modified: application to phosphatase inhibitors and several biochemical findings.
    Hirai G; Sodeoka M
    Acc Chem Res; 2015 May; 48(5):1464-73. PubMed ID: 25894598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries.
    Gozalbes R; Simon L; Froloff N; Sartori E; Monteils C; Baudelle R
    J Med Chem; 2008 Jun; 51(11):3124-32. PubMed ID: 18479119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Bioactive Scaffolds Based on QSAR Models.
    Nakagawa T; Miyao T; Funatsu K
    Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29135084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2014 Apr; 76():427-34. PubMed ID: 24602788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
    Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
    J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.
    Miljković F; Vogt M; Bajorath J
    J Comput Aided Mol Des; 2019 Jun; 33(6):559-572. PubMed ID: 30915709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic assessment of coordinated activity cliffs formed by kinase inhibitors and detailed characterization of activity cliff clusters and associated SAR information.
    Dimova D; Stumpfe D; Bajorath J
    Eur J Med Chem; 2015 Jan; 90():414-27. PubMed ID: 25461890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.